Green tea for ovarian cancer prevention and treatment: A systematic review of the in vitro, in vivo and epidemiological studies

Gynecologic Oncology

Volumn 126, Issue 3, 2012, Pages 491-498

  Trudel, Dominique ^a,b   Labbé, David P ^c,d   Bairati, Isabelle ^a   Fradet, Vincent ^a,e   Bazinet, Laurent ^e   Têtu, Bernard ^a  

^a LAVAL UNIVERSITY   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

Author keywords

Camellia sinensis; Epigallocatechin gallate (EGCG); Epithelial ovarian cancer; Green tea; Human; Meta analysis

Indexed keywords

ASCORBIC ACID; CISPLATIN; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT;

ADD ON THERAPY; ANGIOGENESIS; APOPTOSIS; CANCER CELL CULTURE; CANCER PREVENTION; CANCER THERAPY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; DOWN REGULATION; DRUG POTENTIATION; EMBASE; EPIDEMIOLOGICAL DATA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MEDLINE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TEA; THERAPY EFFECT;

ANIMALS; APOPTOSIS; CATECHIN; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; INCIDENCE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTECTIVE AGENTS; TEA;

EID: 84864414418     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.048     Document Type: Review

References (74)

1. A. Jemal, M.M. Center, E. Ward, and M.J. Thun Cancer occurrence Methods Mol Biol 471 2009 3 29
2. J. Permuth-Wey, and T.A. Sellers Epidemiology of ovarian cancer Methods Mol Biol 472 2009 413 437
3. V. Guarneri, F. Piacentini, E. Barbieri, and P.F. Conte Achievements and unmet needs in the management of advanced ovarian cancer Gynecol Oncol 117 2 2010 152 158
4. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 Suppl. 1 2006 S161 S192
5. Y.J. Surh Cancer chemoprevention with dietary phytochemicals Nat Rev Cancer 3 10 Oct 2003 768 780
6. C.S. Yang, X. Wang, G. Lu, and S.C. Picinich Cancer prevention by tea: animal studies, molecular mechanisms and human relevance Nat Rev Cancer 9 6 2009 429 439
7. D.A. Balentine, S.A. Wiseman, and L.C. Bouwens The chemistry of tea flavonoids Crit Rev Food Sci Nutr 37 8 1997 693 704 (Pubitemid 127349613)
8. M.J. Lee, Z.Y. Wang, H. Li, L. Chen, Y. Sun, and S. Gobbo Analysis of plasma and urinary tea polyphenols in human subjects Cancer Epidemiol Biomarkers Prev 4 4 1995 393 399
9. Z. Ding, S. Kuhr, and U.H. Engelhardt Influence of catechins and theaflavins on the astringent taste of black tea brews Z Lebensm Unters Forsch 195 2 1992 108 111
10. G. Williamson, and C. Manach Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies Am J Clin Nutr 81 1 Suppl. Jan 2005 243S 255S
11. N.T. Zaveri Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications Life Sci 78 18 2006 2073 2080
12. L.M. Butler, and A.H. Wu Green and black tea in relation to gynecologic cancers Mol Nutr Food Res 55 6 Jun 2011 931 940
13. T. Sugiyama, and Y. Sadzuka Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents Biochim Biophys Acta 1653 2 Dec 5 2003 47 59 (Pubitemid 37487647)
14. M.M. Chan, K.J. Soprano, K. Weinstein, and D. Fong Epigallocatechin-3- gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility J Cell Physiol 207 2 2006 389 396
15. M.H. Ravindranath, T.S. Saravanan, C.C. Monteclaro, N. Presser, X. Ye, and S.R. Selvan Epicatechins purified from green tea (Camellia sinensis) differentially suppress growth of gender-dependent human cancer cell lines Evid Based Complement Alternat Med 3 2 Jun 2006 237 247
16. N.M. Yunos, F. Huq, P. Beale, and J.Q. Yu Synergistic interaction between cisplatin and curcumin or epigallocatechin-3-gallate in killing ovarian cancer cells J Biol Inorg Chem 14 2009 S115
17. N.M. Yunos, P. Beale, J.Q. Yu, and F. Huq Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells Anticancer Res 31 4 Apr 2011 1131 1140
18. S.W. Huh, S.M. Bae, Y.W. Kim, J.M. Lee, S.E. Namkoong, and I.P. Lee Anticancer effects of (-)-epigallocatechin-3-gallate on ovarian carcinoma cell lines Gynecol Oncol 94 3 2004 760 768 (Pubitemid 39194472)
19. Y.W. Kim, S.M. Bae, J.M. Lee, S.E. Namkoong, S.J. Han, and B.R. Lee Activity of green tea polyphenol epigallocatechin-3-gallate against ovarian carcinoma cell lines Cancer Res Treat 36 5 Oct 2004 315 323
20. S.D. Rao, and K. Pagidas Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells Anticancer Res 30 7 Jul 2010 2519 2523
21. C. Yan, J. Yang, L. Shen, and X. Chen Inhibitory effect of epigallocatechin gallate on ovarian cancer cell proliferation associated with aquaporin 5 expression Arch Gynecol Obstet Jun 23 2011
22. F. Wilson-Simpson, S. Vance, and H. Benghuzzi Physiological responses of ES-2 ovarian cell line following administration of epigallocatechin-3-gallate (EGCG), thymoquinone (TQ), and selenium (SE) Biomed Sci Instrum 43 2007 378 383 (Pubitemid 46668237)
23. F.A. Mahboub, and F.A. Khorshid The role of green tea extract on the proliferation of human ovarian cancer cells (in vitro) study Int J Cancer Res 6 2 2010 78 88
24. M.W. Roomi, J.C. Monterrey, T. Kalinovsky, M. Rath, and A. Niedzwiecki In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors Oncol Rep 23 3 Mar 2010 605 614
25. M.W. Roomi, V. Ivanov, T. Kalinovsky, A. Niedzwiecki, and M. Rath Inhibition of matrix metalloproteinase-2 secretion and invasion by human ovarian cancer cell line SK-OV-3 with lysine, proline, arginine, ascorbic acid and green tea extract J Obstet Gynaecol Res 32 2 Apr 2006 148 154
26. Z. Yin, E.C. Henry, and T.A. Gasiewicz (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor Biochemistry 48 2 Jan 20 2009 336 345
27. F. Spinella, L. Rosano, S. Decandia, C.V. Di, A. Albini, and G. Elia Antitumor effect of green tea polyphenol epigallocatechin-3-gallate in ovarian carcinoma cells: evidence for the endothelin-1 as a potential target Exp Biol Med (Maywood) 231 6 2006 1123 1127 (Pubitemid 43845590)
28. F. Huq, P. Beale, and J.Q. Yu Studies on new platinums and synergism from drug combination as applied to ovarian cancer cell lines J Biol Inorg Chem 14 2009 S115
29. T. Sugiyama, Y. Sadzuka, K. Tanaka, and T. Sonobe Inhibition of glutamate transporter by theanine enhances the therapeutic efficacy of doxorubicin Toxicol Lett 121 2 Apr 30 2001 89 96 (Pubitemid 32452192)
30. M.G. Goodin, and R.J. Rosengren Epigallocatechin gallate modulates CYP450 isoforms in the female Swiss-Webster mouse Toxicol Sci 76 2 Dec 2003 262 270 (Pubitemid 38035419)
31. Y.H. Kao, R.A. Hiipakka, and S. Liao Modulation of endocrine systems and food intake by green tea epigallocatechin gallate Endocrinology 141 3 2000 980 987 (Pubitemid 32260441)
32. Y. Sadzuka, T. Sugiyama, and S. Hirota Modulation of cancer chemotherapy by green tea Clin Cancer Res 4 1 Jan 1998 153 156 (Pubitemid 28062889)
33. M. Suganuma, S. Okabe, M. Oniyama, Y. Tada, H. Ito, and H. Fujiki Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue Carcinogenesis 19 10 1998 1771 1776 (Pubitemid 28476352)
34. M. Suganuma, S. Okabe, N. Sueoka, E. Sueoka, S. Matsuyama, and K. Imai Green tea and cancer chemoprevention Mutat Res 428 1-2 1999 339 344 (Pubitemid 29389704)
35. T. Sugiyama, and Y. Sadzuka Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma Cancer Lett 133 1 Nov 13 1998 19 26 (Pubitemid 29069107)
36. T. Sugiyama, and Y. Sadzuka Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma Clin Cancer Res 5 2 Feb 1999 413 416 (Pubitemid 29085195)
37. M. Yasokawa, I. Sugimoto, M. Fukuma, N. Goto, N. Kobayashi, and H. Yasuda (-)-Epigallocatechin gallate inhibits Mos activation-mediated Xenopus oocyte maturation induced by progesterone FEBS Lett 463 3 1999 317 320 (Pubitemid 30001942)
38. M. Yoshida, M. Takahashi, K. Inoue, D. Nakae, and A. Nishikawa Lack of chronic toxicity and carcinogenicity of dietary administrated catechin mixture in wistar hannover GALAS rats J Toxicol Sci 36 3 2011 297 311
39. T. Sugiyama, Y. Sadzuka, K. Nagasawa, N. Ohnishi, T. Yokoyama, and T. Sonobe Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin Jpn J Cancer Res 90 7 Jul 1999 775 780 (Pubitemid 29381108)
40. F. Spinella, L. Rosano, V. Di Castro, S. Decandia, A. Albini, and M.R. Nicotra Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma Mol Cancer Ther 5 6 Jun 2006 1483 1492 (Pubitemid 44070485)
41. P. Stocks Cancer mortality in relation to national consumption of cigarettes, solid fuel, tea and coffee Br J Cancer 24 2 1970 215 525
42. L. Wang, I.M. Lee, S.M. Zhang, J.B. Blumberg, J.E. Buring, and H.D. Sesso Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women Am J Clin Nutr 89 3 Mar 2009 905 912
43. T. Byers, J. Marshall, S. Graham, C. Mettlin, and M. Swanson A case-control study of dietary and nondietary factors in ovarian cancer J Natl Cancer Inst 71 4 Oct 1983 681 686 (Pubitemid 14232380)
44. M. Zhang, C.W. Binns, and A.H. Lee Tea consumption and ovarian cancer risk: a case-control study in China Cancer Epidemiol Biomarkers Prev 11 8 2002 713 718 (Pubitemid 34851904)
45. M.T. Goodman, K.H. Tung, K. McDuffie, L.R. Wilkens, and T.A. Donlon Association of caffeine intake and CYP1A2 genotype with ovarian cancer Nutr Cancer 46 1 2003 23 29 (Pubitemid 37163287)
46. Y.J. Song, A.R. Kristal, K.G. Wicklund, K.L. Cushing-Haugen, and M.A. Rossing Coffee, tea, colas, and risk of epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 17 3 2008 712 716 (Pubitemid 351469224)
47. B. Zhou, L. Yang, L. Wang, Y. Shi, H. Zhu, and N. Tang The association of tea consumption with ovarian cancer risk: a metaanalysis Am J Obstet Gynecol 197 6 2007 594 596
48. D.R. Miller, L. Rosenberg, D.W. Kaufman, S.P. Helmrich, D. Schottenfeld, and J. Lewis Epithelial ovarian cancer and coffee drinking Int J Epidemiol 16 1 1987 13 17 (Pubitemid 17029824)
49. C. La Vecchia, E. Negri, S. Franceschi, B. D'Avanzo, and P. Boyle Tea consumption and cancer risk Nutr Cancer 17 1 1992 27 31
50. H. Kuper, L. Titus-Ernstoff, B.L. Harlow, and D.W. Cramer Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer Int J Cancer 88 2 2000 313 318
51. A. Tavani, S. Gallus, L. Dal Maso, S. Franceschi, M. Montella, and E. Conti Coffee and alcohol intake and risk of ovarian cancer: an Italian case-control study Nutr Cancer 39 1 2001 29 34 (Pubitemid 32880945)
52. S.J. Jordan, D.M. Purdie, A.C. Green, and P.M. Webb Coffee, tea and caffeine and risk of epithelial ovarian cancer Cancer Causes Control 15 4 2004 359 365 (Pubitemid 38988025)
53. J.A. Baker, K. Boakye, S.E. McCann, G.P. Beehler, K.J. Rodabaugh, and J.A. Villella Consumption of black tea or coffee and risk of ovarian cancer Int J Gynecol Cancer 17 1 2007 50 54 (Pubitemid 46213969)
54. W. Zheng, T.J. Doyle, L.H. Kushi, T.A. Sellers, C.P. Hong, and A.R. Folsom Tea consumption and cancer incidence in a prospective cohort study of postmenopausal women Am J Epidemiol 144 2 1996 175 182 (Pubitemid 26234996)
55. S.C. Larsson, and A. Wolk Tea consumption and ovarian cancer risk in a population-based cohort Arch Intern Med 165 22 2005 2683 2686 (Pubitemid 41785069)
56. S.A. Silvera, M. Jain, G.R. Howe, A.B. Miller, and T.E. Rohan Intake of coffee and tea and risk of ovarian cancer: a prospective cohort study Nutr Cancer 58 1 2007 22 27 (Pubitemid 47076158)
57. M.A. Gates, S.S. Tworoger, J.L. Hecht, V.I. De, B. Rosner, and S.E. Hankinson A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer Int J Cancer 121 10 2007 2225 2232 (Pubitemid 47585602)
58. S.S. Tworoger, D.M. Gertig, M.A. Gates, J.L. Hecht, and S.E. Hankinson Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer Cancer 112 5 2008 1169 1177 (Pubitemid 351304604)
59. J. Steevens, L.J. Schouten, B.A. Verhage, R.A. Goldbohm, and P.A. van den Brandt Tea and coffee drinking and ovarian cancer risk: results from the Netherlands Cohort Study and a meta-analysis Br J Cancer 97 9 2007 1291 1294 (Pubitemid 350035805)
60. M. Zhang, A.H. Lee, C.W. Binns, and X. Xie Green tea consumption enhances survival of epithelial ovarian cancer Int J Cancer 112 3 2004 465 469 (Pubitemid 39390612)
61. C.M. Nagle, C.M. Olsen, C.J. Bain, D.C. Whiteman, A.C. Green, and P.M. Webb Tea consumption and risk of ovarian cancer Cancer Causes Control 21 9 May 20 2010 1485 1491
62. M.H. Kweon, V.M. Adhami, J.S. Lee, and H. Mukhtar Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate J Biol Chem 281 44 Nov 3 2006 33761 33772 (Pubitemid 46036754)
63. M.A. Gates, A.F. Vitonis, S.S. Tworoger, B. Rosner, L. Titus-Ernstoff, and S.E. Hankinson Flavonoid intake and ovarian cancer risk in a population-based case-control study Int J Cancer 124 8 2009 1918 1925
64. A. Bagnato, and L. Rosano The endothelin axis in cancer Int J Biochem Cell Biol 40 8 2008 1443 1451
65. A. Bhalla, S. Haque, I. Taylor, M. Winslet, and M. Loizidou Endothelin receptor antagonism and cancer Eur J Clin Invest 39 Suppl. 2 Jun 2009 74 77
66. A. Willems, K. Gauger, C. Henrichs, and N. Harbeck Antibody therapy for breast cancer Anticancer Res 25 3A 2005 1483 1489 (Pubitemid 40896753)
67. K.L. White, D.N. Rider, K.R. Kalli, K.L. Knutson, G.P. Jarvik, and E.L. Goode Genomics of the NF-kappaB signaling pathway: hypothesized role in ovarian cancer Cancer Causes Control 22 5 May 2011 785 801
68. C.G. Evans, L. Chang, and J.E. Gestwicki Heat shock protein 70 (hsp70) as an emerging drug target J Med Chem 53 12 Jun 24 2010 4585 4602
69. H.H. Chow, I.A. Hakim, D.R. Vining, J.A. Crowell, J. Ranger-Moore, and W.M. Chew Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals Clin Cancer Res 11 12 2005 4627 4633 (Pubitemid 40825654)
70. K.M. Pisters, R.A. Newman, B. Coldman, D.M. Shin, F.R. Khuri, and W.K. Hong Phase I trial of oral green tea extract in adult patients with solid tumors J Clin Oncol 19 6 2001 1830 1838 (Pubitemid 32230886)
71. S.A. Laurie, V.A. Miller, S.C. Grant, M.G. Kris, and K.K. Ng Phase I study of green tea extract in patients with advanced lung cancer Cancer Chemother Pharmacol 55 1 2005 33 38 (Pubitemid 40064493)
72. A. du Bois, M. Quinn, T. Thigpen, J. Vermorken, E. Avall-Lundqvist, and M. Bookman 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) Ann Oncol 16 Suppl. 8 2005 viii7 viii12 (Pubitemid 41631227)
73. D. Labbé, A. Tremblay, and L. Bazinet Effect of brewing temperature and duration on green tea catechin solubilization: basis for production of EGC and EGCG-enriched fractions Sep Purif Technol 49 2006 1 9
74. D. Labbé, B. Têtu, D. Trudel, and L. Bazinet Catechin stability of EGC- and EGCG-enriched tea drinks produced by a two-step extraction procedure Food Chem 111 1 2008 139 143